KSR1 调解小细胞肺癌 瘤启动和 Cisplatin 耐药性
Deepan Chatterjee1, Robert A Svoboda2, Dianna H Huisman2
1University of Nebraska Medical Center, Omaha, NE, United States.
Molecular cancer research : MCR
|February 10, 2025
概括
拉斯1的激酶抑制剂 (KSR1) 通过调节瘤发起细胞,驱动小细胞肺癌 (SCLC) 瘤启动和西斯普拉丁耐药性. 在SCLC细胞中破坏KSR1增强了西斯的疗效,并防止了耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 小细胞肺癌 (SCLC) 预后不好,治疗进展有限.
- 瘤发起细胞 (TIC) 是SCLC耐药性和复发的关键驱动因素.
- 针对ICT对于改善SCLC治疗结果至关重要.
研究的目的:
- 为了确定SCLC TICs和西斯普拉丁耐药性的新型调节剂.
- 为了研究Ras 1 (KSR1) 激酶抑制剂在SCLC中的作用.
- 评估KSR1作为SCLC的潜在治疗点.
主要方法:
- 在SCLC细胞系中进行CRISPR/Cas9介导的KSR1淘汰.
- 在体外极限限稀释分析 (ELDA) 评估TIC频率.
- 在体内H82瘤异种移植模型来评估西斯普拉丁耐药性.
- 药理学ERK抑制和KSR1.1的突变分析.
主要成果:
- 在多种亚型的SCLC细胞中,KSR1淘汰预防了超过90%的思普拉丁耐药性.
- 在实验室中,KSR1的干扰显著增强了思普拉丁降低SCLCTIC的能力.
- 在SCLC瘤异种移植中,KSR1淘汰阻止了西斯普拉丁耐药性.
- 与KSR1的ERK相互作用,但不仅仅是ERK激活,对于KSR1介导的西斯普拉丁耐药性至关重要.
结论:
- KSR1是SCLCTIC形成的关键调节者,瘤开始,以及对西斯普拉丁的耐药性.
- KSR1是克服SCLC治疗耐药性的潜在治疗标.
- 准KSR1可能为改善SCLC患者在各种亚型的治疗结果提供了一种新的策略.
更多相关视频
05:11Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
Published on: May 10, 2024
884
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
相关概念视频
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K